Full-Time

Director of Product Marketing

Pattern Bioscience

Pattern Bioscience

51-200 employees

AI-driven rapid bacterial ID and AST

No salary listed

Austin, TX, USA

Hybrid

Remote option available with travel; hybrid in Austin, TX preferred.

Category
Product (1)
Required Skills
Market Research
Requirements
  • Bachelor’s degree in Science, Microbiology or related field
Responsibilities
  • Own the launch of Pattern’s Pneumonia ID/AST solution, including positioning, messaging, sales training and tools, pricing and other launch related deliverables
  • Support the sales organization and customers by providing technical information about products, technology, or other issues requiring marketing input or assistance
  • Serve as the company expert with respect to disease state, standard of care, clinical and economic data, competition, and market access. Ensure routine and real-time communication of updates to the field, senior management and customer support organizations.
  • Cultivate and maintain relationships with KOLs, corporate partners and VIP customers that will drive platform adoption and endorsements
  • Responsible for lifecycle management for product lines including tracking success and managing resolution of issues
  • Lead the development of the marketing department and manage direct reports
  • Support the product development organization by representing the voice of the customer throughout the entire life cycle of the system
  • Create strategic and tactical marketing plans to drive growth for existing and new lines of business
  • Perform market research and gather customer feedback in order to define, prioritize and develop corresponding justifications for market requirements of new products
  • Manage the assigned marketing budget to ensure spending is gated appropriately and budget is not exceeded
  • Contribute to the company strategic planning and annual planning/budgeting process.
Desired Qualifications
  • MBA or advanced technical degree (MS, PhD) preferred
  • Experience in infectious disease diagnostics and launching new, innovative products highly preferred
  • Thorough knowledge of US Hospital Diagnostic Lab customer profile and purchasing process
  • Experience with US market access, clinical outcome and economic business case marketing is a plus
  • Experience in and comfort with pre-revenue startups is a plus
  • Design, streamline, and communicate processes effectively
  • Excel in tactical execution with strong attention to detail while maintaining a strategic, big picture vision
  • Identify ways to remove operational friction and inefficiency, digging into problems and finding creative and compliant solutions
  • Are flexible, adaptable, and comfortable moving through uncertainty to recommend and make decisions
  • Thrive in low-infrastructure, fast-changing environments where you switch regularly between areas of responsibility, priorities and levels of work
  • Foster strong cross-department relationships and pursue collaborative buy-in

Pattern Bioscience develops rapid clinical diagnostics that identify bacterial infections and determine antibiotic resistance. Its system uses single-cell analysis with AI pattern recognition to deliver definitive ID/AST results in about four hours. The product suite includes diagnostic devices, consumables, service contracts, and software for AI analysis. By speeding and improving accuracy, Pattern Bioscience aims to help hospitals reduce inappropriate antibiotic use and combat antibiotic resistance.

Company Size

51-200

Company Stage

Series D

Total Funding

$91.6M

Headquarters

Austin, Texas

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • $43M Series D funding from AMR Action Fund supports FDA 510(k) submission.
  • $40.9M BARDA contract accelerates pneumonia and bacteremia panel development.
  • Over 1,000 samples enrolled in multi-center trial for Q3 regulatory push.

What critics are saying

  • Accelerate Diagnostics' PhenoVue captures market with FDA-cleared 3-hour AST.
  • BioFire's FilmArray dominates ICU syndromic testing, sidelining single-pathogen focus.
  • Clinical trial failure by mid-2026 exhausts Series D runway, halting launch.

What makes Pattern Bioscience unique

  • Digital CultureTM enables culture-free phenotypic ID/AST in four hours.
  • Single-cell analysis captures all resistance mechanisms unlike genotypic tests.
  • Pneumonia ID/AST Panel targets critically ill patients with FDA Breakthrough Designation.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pattern Bioscience who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

-1%
Legal Desire
Nov 19th, 2025
Pattern Bioscience Raises $43M Series D

Pattern Bioscience has raised $43 million in Series D funding, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funds will support a US multi-center clinical trial and regulatory submission for their Pneumonia ID/AST Panel, which has FDA Breakthrough Device Designation and is backed by a BARDA contract worth up to $40.9 million. Latham & Watkins LLP represented Pattern Bioscience in the transaction.

VCBay
Apr 29th, 2023
Austin-based Biotech startup Pattern Bioscience raises USD 28.7 million in Series C funding

To quickly develop effective treatments for drug-resistant bacterial infections, Pattern is a leader in the application of single-cell microbiology.

Business Wire
Apr 28th, 2023
Pattern Bioscience Secures $28.7 Million in Series C Financing

Pattern Bioscience secures $28.7 million in Series C financing to accelerate development of first-of-its-kind infectious disease diagnostic platform

FinSMEs
Apr 27th, 2023
Pattern Bioscience Raises $28.7M in Series C Financing

Pattern Bioscience, an Austin, TX-based company which specializes in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, raised $28.7M in Series C funding.

360Dx
Apr 27th, 2023
Pattern Bioscience Closes $28.7M Series C Financing Round | 360Dx

Including the Series C round, Pattern has now raised $68 million to date, the company said in a statement.